We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Antibe Therapeutics Inc | TSX:ATE | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.295 | 0.01 | 0.01 | 0 | 12:00:15 |
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the election of directors are provided below:
Director Nominee
Outcome
% For
% Withheld
Roderick Flower
Elected
90.77%
9.23%
Robert E. Hoffman
Elected
81.08%
18.92%
Amal Khouri
Elected
90.74%
9.26%
Dan Legault
Elected
90.62%
9.38%
Walt Macnee
Elected
90.81%
9.19%
Jennifer McNealey
Elected
80.31%
19.69%
Yung Wu
Elected
90.80%
9.20%
Voting results on all matters voted on at the Meeting have been filed on SEDAR.
About Antibe Therapeutics Inc. Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation therapies to target inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today’s NSAIDs for acute pain. Antibe’s second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230908760977/en/
Antibe Therapeutics Inc. Christina Cameron VP Investor Relations +1 416-577-1443 christina@antibethera.com
1 Year Antibe Therapeutics Chart |
1 Month Antibe Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions